Clinical trials: Diabetic Oculopathy
Macular Edema, Cataract
Preoperative Topic Diclofenac as a Prevention of Postoperative Macular Edema in Patients With Diabetic Retinopathy
Diabetes has many negative effects on patients' general health. Among many other consequences it speeds up the cataract formation and that is why diabetic patients need cataract surgery very often.
- Conditions
- Macular Edema, Cataract, Diabetic Retinopathy
- Trial name
- NCT01694212
- Testing
- Perioperative Diclofenac eye-drops administration
- Where
- Croatia
- Volunteers
- 55 people
- Sponsor
- Eye Clinic Medic Zuljan Jukic
Diabetic Retinopathy
Pivotal Trial to Assess the Clinical Performance of Ophthal-360 for the Detection of Diabetic Retinopathy
Multicenter, prospective, study to assess the performance of the Ophthal-360 platform in the diagnosis of more-than-mild Diabetic Retinopathy (mtmDR) in diabetic patients with no previous diagnosis of DR.
- Trial name
- NCT05806957
- Testing
- Fundus Photography
- Volunteers
- 500 people
- Sponsor
- Ophthalytics, Inc.
Diabetic Retinopathy, Age-Related Macular Degeneration
Validation of Bulbicam for DR- and AMD-patients
Aim To investigate repeatability and stability of the six OTH-related Bulbicam tests in patients suffering from a) Diabetic retinopathy (DR), b) Age related macular degeneration (AMD) and matched healthy controls (HC).
- Trial name
- NCT05441072
- Testing
- BulbiCam
- Where
- Norway
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Meddoc
Visual Impairment, Age-Related Macular Degeneration
A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training
In this study, the study team utilize virtual reality (VR) to simulate visual impairments of different types and severity in healthy subjects.
- Conditions
- Visual Impairment, Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
- Trial name
- NCT05135195
- Testing
- In-House Developed VR Platform - AMD, DR, Glaucoma, In-House Developed VR Platform - Glaucoma
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Diabetic Retinopathy
Treatment for Completers of the Study B7A-MC-MBCM
To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study (NCT00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment.
- Trial name
- NCT00266695
- Testing
- Ruboxistaurin
- Where
- 29 sites in United States
- Volunteers
- 203 people
- Sponsor
- Chromaderm, Inc.
Diabetic Retinopathy
Implementation of Teleophthalmology in Urban Health Systems Study
This study is being conducted to test the effectiveness of I-SITE (Implementation for Sustained Impact in Teleophthalmology), an implementation program to sustain increased diabetic eye screening rates using teleophthalmology in…
- Trial name
- NCT05773495
- Testing
- I-SITE Intervention, Usual Care Teleophthalmology
- Where
- United States
- Volunteers
- 12,840 people
- Sponsor
- University of Wisconsin, Madison
Diabetic Retinopathy
Verisee Software for Diabetic Retinopathy Screening
The investigators aim to improve the diagnostic accuracy and the clinical referral rate for diabetic retinopathy by using a deep learning-based software.
- Trial name
- NCT04631653
- Testing
- VeriSee®
- Where
- Taiwan
- Volunteers
- 1,000 people
- Sponsor
- Taichung Veterans General Hospital
Proliferative Diabetic Retinopathy, Age Related Macular Degeneration
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
Aims of the trial: Establishing the profile of the growth factors and other mediators of angiogenesis in different ocular fluids (aqueous humour, vitreous gel and ocular liquid in vitrectomized eyes), in the 2 most frequent…
- Trial name
- KIA-ProRet (NCT00776763)
- Testing
- Avastin intravitreal injection
- Where
- Romania
- Volunteers
- 150 people
- Sponsor
- Ophthalmological Association Edelweiss
Eye Disease, Eye Care
Tailored Messages to Increase Eye Examination Behavior
The purpose of this project is to test two different types of health messages, one that is developed for a specific group (targeted) and the other that is more personalized to individuals (tailored), to see which is better at…
- Trial name
- NCT00649766
- Testing
- tailored newsletter, targeted newsletter
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Diabetic Retinopathy
PASCAL Laser Platform Produces Less Pain Responses Compared To Conventional Laser System
The aim of this study is to compare the severity of expressed pain scores in patients with PDR who underwent either PASCAL or conventional laser and to assess the association between patient characteristics and severity of pain.
- Trial name
- NCT02645383
- Testing
- PASCAL laser, Conventional laser
- Volunteers
- 30 people
- Sponsor
- Kocatepe University
Diabetic Retinopathy
Phenotyping Diabetic Retinopathy
The purpose of this study is to validate and characterize phenotypes of diabetic retinopathy (DR) progression based on available clinical data (demographic, systemic and ophthalmic data).
- Trial name
- NCT00840541
- Where
- Portugal
- Volunteers
- 80 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Proliferative Diabetic Retinopathy, Diabetic Retinopathy
Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.
In prolifertive diabetic retinopathy (PDR) eyes with bleeding known as vitreous hemorrhage (VH) requiring a surgical procedure to remove the vitreous, called a vitrectomy, we will determine if the benefit and safety of adding a…
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
- Trial name
- 4 PORT (NCT07864480)
- Testing
- PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Southeast Retina Center, Georgia
Diabetic Retinopathy
OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy
The purpose of this study is to determine whether supplementation with OcuStem, a nutritional supplement, will reduce the progression of mild to moderate diabetic retinopathy.
- Trial name
- NCT02353923
- Testing
- OcuStem Supplementation
- Volunteers
- 30 people
- Sponsor
- Aidan Products LLC
Diabetic Macular Edema, Diabetic Retinopathy
A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
A Phase 2 study to determine the safety and preliminary efficacy of intravitreal injections of AVD-104, a novel glyco-mimetic nanoparticle, in reducing macular edema associated with diabetic retinopathy.
- Trial name
- NCT06181227
- Testing
- AVD-104
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Aviceda Therapeutics, Inc.
Diabetic Retinopathy
A Single-center, Retrospective Study to Evaluate the Clinical Performance of Artificial Intelligence Medical Assisted Diagnostic Software (VeriSee DR) for Screening of Diabetic Retinopathy in Patients With Diabetes Mellitus
This study is to evaluate the clinical performance of VeriSee DR for DR screening from color fundus photography images in patients with diabetes mellitus.
- Trial name
- NCT04160988
- Where
- Taiwan
- Volunteers
- 703 people
- Sponsor
- Acer Being Health Inc.
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment.
- Trial name
- LRTforDME+PRP (NCT00445003)
- Testing
- Ranibizumab, Triamcinolone Acetonide, Focal/grid laser
- Where
- 56 sites in United States
- Volunteers
- 333 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema
Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery
Triamcinolone has already been used by different routes of administration to treat diabetic macular edema. In the present study, intravitreal injection (IVI) and posterior sub-Tenon's infusion (STI) of triamcinolone acetonide…
- Trial name
- NCT00801450
- Testing
- Triamcinolone acetonide
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- University of Sao Paulo
Age-Related Macular Degeneration, Diabetic Maculopathy
Selective RPE Laser Treatment (SRT) for Various Macular Diseases
In this prospective clinical study SRT is performed with various pulse durations at 1.7µs and additionally 200ns to evaluate the different clinical effects of both laser regimens.
- Conditions
- Age-Related Macular Degeneration, Diabetic Maculopathy, Central Serous Chorioretinopathy
- Trial name
- NCT00403884
- Testing
- Selective RPE laser treatment
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Regensburg
Diabetes, Diabetic Retinopathy
Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device
Diabetes affects over 37 million Americans and over 530 million people globally. Each diabetic patient needs at least one retinal exam per year starting immediately at the time of diagnosis if they have Type II diabetes (and…
- Conditions
- Diabetes, Diabetic Retinopathy, Diabetic Macular Edema, Diabetic Eye Problems
- Trial name
- NCT05368623
- Testing
- Color fundus photograph, Optical Coherence Tomography (OCT) of the retina, Mydriatic Agent
- Where
- 3 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- RETINA-AI Health, Inc.
Diabetic Macular Edema (DME)
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial to Evaluate the Safety, Efficacy, and Durability of a Single Intravitreal Injection of 4D-150 versus Aflibercept in Adults with Diabetic Macular Edema (4SIGHT)
- Trial name
- 4SIGHT (NCT07867080)
- Testing
- 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 87 sites in United States, China and 1 more
- Volunteers
- 514 people
- Sponsor
- 4D Molecular Therapeutics